FDA staff: J&J diabetes drug may pose heart risk

Federal drug reviewers think Johnson & Johnson's experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.

In documents just released, Food and Drug Administration staff experts conclude studies showed canagliflozin (kann-AH'glih-floh-zin) slightly increased complications and risk of a urinary tract infection. That's because the pill works by boosting blood sugar excretion via urine.

The studies didn't find other serious problems, such as weakening of bones, damage to the liver or kidneys, or various cancers.

If the FDA approves the New Brunswick, N.J., company's , it would be the first in a new class of Type 2 diabetes medicines, called SGLT2 inhibitors.

Outside advisers to the FDA will review the data during a meeting Thursday and recommend whether the agency should approve canagliflozin.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Experimental diabetes drugs offer patients hope

Jun 11, 2012

Some experimental diabetes treatments in late testing offer patients hope of better controlling their blood sugar and weight and preventing dangerously low blood sugar, all big challenges for millions of diabetics.

FDA: Bristol-Myers diabetes drug appears safe

Mar 30, 2009

(AP) -- A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.

FDA backs Vytorin for kidney disease patients

Oct 31, 2011

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

Recommended for you

Big cities take aim at prescription painkillers

20 hours ago

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

21 hours ago

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments